Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK 208108
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
GSK 208108 is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist that was developed by GSK for the acute treatment of migraine. Uniquely among CGRP antagonists, it was formulated for delivery via inhalation to achieve rapid systemic absorption and fast onset of therapeutic effect, bypassing the gastrointestinal tract. The compound was evaluated in Phase 1 clinical trials to assess safety, tolerability, and pharmacokinetics, but development was ultimately discontinued by the sponsor.
02
Targets
Calcitonin gene-related peptide type 1 receptor
Beyond the preview
Go deeper on GSK 208108.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK 208108.